ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Orionis Biosciences launches with Novartis pact

by Lisa M. Jarvis
March 7, 2020 | APPEARED IN VOLUME 98, ISSUE 9

 

Orionis Biosciences has debuted with a 4-year pact with the big drug company Novartis to develop allosterically acting small molecules that when bound to a protein change its conformation to allow binding to a protein target of interest. That protein-protein interaction could prompt the target to be turned off, modulated, or broken down. Orionis says its allosteric-binding technology, which it calls Allo-Glue, could allow it to access previously intractable protein targets. As part of the deal, Novartis is providing undisclosed research funding and investment in the firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment